# IPCALAB (IPCALAB) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/ipcalab

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,009.6
- Change: +1.99%
- As of: 2026-09-18
- 1D return: +1.99%
- 5D return: +1.96%
- 1M return: +5.76%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, IPCALAB is trading at ₹2009.6, indicating a strong bullish technical stance across multiple timeframes. Daily, weekly, and monthly indicators show the price trading above key moving averages (EMA 20, EMA 50, SMA 20, SMA 50, SMA 200) and the Supertrend indicator, suggesting consistent upward momentum. The daily trend shows a strong positive ADX of 28.42 with the plus DI (23.01) above the minus DI (13.79), reinforcing the bullish trend. Weekly and monthly timeframes also exhibit bullish Supertrend directions and positive ADX values (40.89 and 21.4 respectively), indicating alignment across timeframes. Recent market activity includes 3 positive attention events in the last 30 days, with no downside events. The stock has formed a Hammer and an Outside Bar pattern on the weekly timeframe as of September 18, 2026.

Nearest support is observed around ₹1974.07 (1.77% below current price), followed by ₹1934.13 (3.76% below). Overhead resistance is noted at ₹2010.23 (0.03% above current price), with further levels at ₹2050.17 (2.02% above) and ₹2086.33 (3.82% above). The stock is trading near the upper end of its recent trading range, with its position in the 20-day range at 81%, 50-day range at 92%, and 252-day range at 96%. The annualized volatility stands at 32%, with a maximum drawdown of -27% observed historically. The current setup carries risk associated with its proximity to resistance levels and high position within its trading ranges.

- IPCALAB's current price is ₹2009.6 as of September 18, 2026.
- Daily, weekly, and monthly technical indicators are aligned bullishly, with the price trading above key moving averages and Supertrend.
- Nearest support levels are ₹1974.07 and ₹1934.13.
- Nearest resistance levels are ₹2010.23 and ₹2050.17.
- Watch for a sustained break above ₹2010.23 resistance or a move towards support levels around ₹1974.07.

- Hammer
- Outside Bar
- Bullish Engulfing Reversal
- Harami
- Evening Star
- Doji

### What Changed

Ipca Laboratories' stock traded on the NSE saw a recent price increase. On September 18, 2026, the stock closed at ₹2009.6, up from its previous close of ₹1970.3. This price movement occurred within a broader market context where the Indian stock market was expected to open quietly on September 18, 2026, following mixed global cues. Analysts were suggesting monitoring key resistance and support levels amid ongoing geopolitical concerns.

- On September 18, 2026, Ipca Laboratories' stock closed at ₹2009.6.
- This represents an increase from the previous closing price of ₹1970.3.
- The observation date for the latest price is September 18, 2026.
- Recent news on September 18, 2026, indicated analysts were advising market participants to monitor key resistance and support levels due to geopolitical concerns.

- Stock market today: Trade guide for Sensex, Nifty 50, crude oil and gold | Eight stocks to buy

### Official Filings

IPCA Laboratories reported a significant increase in its first quarter (Q1) of fiscal year 2027 (FY27) financial performance. Consolidated revenue grew by 21% to ₹2,788 crores compared to the same period in FY26, reaching ₹2,309 crores. This growth was accompanied by an improvement in the consolidated Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margin, which rose to 22.88% from 18.39% in the prior year. The company also revised its FY27 revenue growth guidance upwards to a range of 14%-16%, an increase from the previous 12%-13% forecast, and raised its consolidated EBITDA margin guidance to 23% from 22%. This positive financial update was discussed in an analyst and investor call on August 14, 2026. Additionally, the company's 76th Annual General Meeting (AGM) was held on August 13, 2026, where all proposed resolutions were passed, including the adoption of audited financial statements for the year ended March 31, 2026, and the declaration of a dividend. Key management personnel, including directors Ajit Kumar Jain, Pranay Godha, and Prashant Godha, secured re-appointments for executive roles.

- On August 17, 2026, Ipca Laboratories announced Q1 FY27 consolidated revenue of ₹2,788 crores, a 21% increase from ₹2,309 crores in Q1 FY26.
- Consolidated EBITDA margin improved to 22.88% in Q1 FY27 from 18.39% in Q1 FY26.
- The company raised its FY27 revenue growth guidance to 14%-16% and its consolidated EBITDA margin guidance to 23%.
- On August 13, 2026, the company's Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, showing standalone revenue of ₹2,119.24 crores and consolidated revenue of ₹2,788.10 crores.
- At the AGM on August 13, 2026, all resolutions were passed, including the adoption of FY26 audited financial statements and the declaration of a dividend.

- IPCA Laboratories Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Ipca Laboratories Limited has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL
- IPCA Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 13, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- IPCA Laboratories Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- IPCA LABORATORIES LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL
- IPCA Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. |SUBJECT: Outcome of Board Meeting
- IPCA Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 13, 2026 |SUBJECT: Shareholders meeting

### Fundamentals

Ipca Laboratories reported revenue from operations of ₹2,788.10 crore for Q1 FY2026-27. This represents a sequential increase from ₹2,388.48 crore in Q4 FY2025-26 and ₹2,392.50 crore in Q3 FY2025-26. Profit Before Exceptional Items and Tax was ₹572.08 crore in Q1 FY2026-27, up from ₹450.27 crore in Q4 FY2025-26 and ₹428.33 crore in Q3 FY2025-26. Profit After Tax (Profit Loss For Period) followed a similar trend, reaching ₹424.27 crore in Q1 FY2026-27, compared to ₹306.69 crore in Q4 FY2025-26 and ₹363.67 crore in Q3 FY2025-26. The company's finance costs were ₹11.88 crore in Q1 FY2026-27, a decrease from ₹20.20 crore in Q4 FY2025-26 and ₹17.62 crore in Q3 FY2025-26. Tax expense for Q1 FY2026-27 was ₹149.27 crore.

- Revenue from operations for Q1 FY2026-27 stood at ₹2,788.10 crore.
- Profit Before Exceptional Items and Tax increased to ₹572.08 crore in Q1 FY2026-27.
- Profit After Tax for Q1 FY2026-27 was ₹424.27 crore.
- Finance costs decreased to ₹11.88 crore in Q1 FY2026-27.
- Tax expense for Q1 FY2026-27 was ₹149.27 crore.

### Bull Case

Ipca Laboratories' stock is exhibiting technical strength across multiple timeframes. The daily trend shows the closing price at ₹2009.6, significantly above its 20-day Exponential Moving Average (EMA) of ₹1941.8 and its 50-day Simple Moving Average (SMA) of ₹1860.81. The Supertrend indicator is also 'bullish' on a daily basis, suggesting upward momentum. This positive trend extends to the weekly and monthly timeframes, with the Supertrend indicator remaining 'bullish' and the closing price trading above key moving averages. The stock has also demonstrated strong returns over the past year, with a return of 50% in the last 12 months and a year-to-date return of 44%.

- The daily Supertrend indicator is 'bullish' as of September 18, 2026.
- The closing price of ₹2009.6 on September 18, 2026, is above the 20-day EMA (₹1941.8) and 50-day SMA (₹1860.81).
- The stock has delivered a 50% return over the past year and a 44% return year-to-date.
- The monthly Supertrend indicator is also 'bullish'.

- Stock market today: Trade guide for Sensex, Nifty 50, crude oil and gold | Eight stocks to buy

### Bear Case

The company's stock is trading near a resistance level, with the nearest identified at ₹2010.23, approximately 0.03% above the current price of ₹2009.6. While the stock has shown positive returns over various periods, including a 0.50 return over the past year, its annualized volatility stands at 0.32. The maximum drawdown observed was -0.27, indicating historical periods of significant price decline. The Average True Range (ATR) at 2.8% suggests potential for price fluctuations.

- The stock is trading at ₹2009.6 as of 2026-09-18, close to a resistance level of ₹2010.23.
- The annualized volatility is 0.32.
- The maximum observed drawdown for the stock is -0.27.
- The Average True Range (ATR) is 2.8%.

- Stock market today: Trade guide for Sensex, Nifty 50, crude oil and gold | Eight stocks to buy

### FAQs

**What were Ipca Laboratories' key financial results for Q1 FY27 and how did they compare to the previous year?**

For Q1 FY27, Ipca Laboratories reported consolidated revenue of ₹2,788 crores, an increase of 21% from ₹2,309 crores in Q1 FY26. The consolidated EBITDA margin also improved to 22.88% from 18.39% in the prior year's comparable quarter. Domestic formulation revenue grew by 13% to ₹1,082 crores, and export revenue saw a significant increase of 34% to ₹603 crores.

**How has Ipca Laboratories updated its financial guidance for FY27?**

Ipca Laboratories has revised its FY27 revenue growth guidance upward to a range of 14%-16%, an increase from the previous guidance of 12%-13%. The company also raised its consolidated EBITDA margin guidance to 23%, up from the earlier projection of 22%.

**What were the outcomes of the Annual General Meeting (AGM) held on August 13, 2026?**

At the 76th AGM held on August 13, 2026, all proposed resolutions were passed. This included the adoption of the audited financial statements for the year ended March 31, 2026, the declaration of a dividend, and the re-appointment of directors Ajit Kumar Jain, Pranay Godha, and Prashant Godha as Executive Directors for a five-year term starting August 16, 2026. Shareholder approval was also given for the remuneration of cost auditors for the 2026-27 financial year.

**What is the current technical trend and key price levels for Ipca Laboratories?**

As of September 18, 2026, the daily and weekly technical trends for Ipca Laboratories are indicated as bullish, with the Supertrend indicator at 1837.91 on a daily basis and 1619.76 on a weekly basis. Key price levels to monitor include immediate resistance near ₹2010.23 and support around ₹1974.07.

- Stock market today: Trade guide for Sensex, Nifty 50, crude oil and gold | Eight stocks to buy
- IPCA Laboratories Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Ipca Laboratories Limited has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL
- IPCA Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 13, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- IPCA Laboratories Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- IPCA LABORATORIES LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,974.07
- Risk regime: Price Risk Currently Contained

### Support levels
- 1907.9
- 1499.3027832031248
- 1470

### Resistance levels
- 2050.1666666666665
- 2086.333333333333

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +1.99% |
| return_10 | +2.74% |
| return_1m | +6.77% |
| return_1y | +49.88% |
| return_20 | +5.76% |
| return_3m | +30.19% |
| return_5 | +1.96% |
| return_6m | +30.19% |
| return_since_start | +18.70% |
| return_ytd | +43.73% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -27.26% |
| annualized_volatility | +32.15% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Expands Over 20 Percent Year-On-Year While Net Profit Grows More Than 80 Percent

The company reported higher revenue and significantly higher profit for the quarter ended 30 June 2026 compared to the same period last year. Revenue from operations increased by 20.76 percent year-on-year to ₹2,788.10 crore. Profit for the period rose by 82.18 percent to ₹424.27 crore. The faster profit growth was supported by a reduction in finance costs.

## Revenue Growth and Sequential Trends

Revenue from operations rose by ₹399.62 crore, or 16.73 percent, compared to the immediately preceding quarter ended 31 March 2026. On a year-on-year basis, the increase was ₹479.25 crore, representing a 20.76 percent rise from the quarter ended 30 June 2025.

The sequential increase follows two quarters where revenue had remained relatively stable, at ₹2,392.50 crore in the December 2025 quarter and ₹2,388.48 crore in the March 2026 quarter. The current quarter’s revenue of ₹2,788.10 crore marks a clear step up from that level.

## Profitability and Exceptional Items

Profit before tax increased by 73.09 percent year-on-year, rising from ₹330.51 crore to ₹572.08 crore. Profit for the period grew by 82.18 percent, from ₹232.89 crore to ₹424.27 crore.

A notable factor in the sequential comparison involves exceptional items. In the quarter ended 31 March 2026, profit before exceptional items was ₹450.27 crore, while profit before tax was ₹404.45 crore, indicating an exceptional loss of approximately ₹45.82 crore. In the current quarter, profit before exceptional items and profit before tax were identical at ₹572.08 crore, meaning no such exceptional charges were recorded. The absence of that loss contributed to the sharper rise in reported profit relative to the previous quarter.

## Expense Composition and Finance Costs

The major expense items for the quarter ended 30 June 2026 included cost of materials consumed at ₹638.14 crore, employee benefit expense at ₹601.56 crore, and other expenses at ₹719.68 crore. Depreciation and amortisation amounted to ₹110.81 crore.

Finance costs declined both sequentially and year-on-year. They fell by 41.19 percent from ₹20.20 crore in the previous quarter to ₹11.88 crore. Compared to the same quarter last year, finance costs decreased by 35.82 percent from ₹18.51 crore. This reduction in financing charges contributed to the improvement in pre-tax profit.

## Tax and Earnings Per Share

Tax expense increased by 55.34 percent year-on-year, from ₹96.09 crore to ₹149.27 crore. Because profit before tax grew at a faster rate, the effective tax rate moved from approximately 29.1 percent in the prior-year quarter to 26.1 percent in the current quarter.

Basic earnings per share from continuing operations rose to ₹15.84, up 72.36 percent from ₹9.19 in the same quarter last year. The paid-up value of equity share capital remained unchanged at ₹25.37 crore throughout the period.

## Key Takeaway

The quarter ended 30 June 2026 saw revenue increase by over 20 percent year-on-year, while profit for the period grew by 82.18 percent. The profit improvement was supported by lower finance costs and, on a sequential basis, the absence of an exceptional loss that had affected the previous quarter. Earnings per share increased by 72.36 percent year-on-year.

### Ratios

## Official filings

- 2026-08-17 — Generic Announcement: IPCA Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_17082026120645_IpcaConcallTranscript14082026.pdf)
- 2026-08-17 — Generic Announcement: IPCA Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1224_WebXMLFile_20260817_120440734.xml)
- 2026-08-14 — Generic Announcement: IPCA Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_14082026110940_IpcaVotingResultsandScrutinizerReport.pdf)
- 2026-08-14 — Generic Announcement: IPCA Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_14082026172456_IpcaConferenceCallAudiolink.pdf)
- 2026-08-14 — Generic Announcement: IPCA Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1224_WebXMLFile_20260814_172148243.xml)
- 2026-08-14 — Generic Announcement: IPCA Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_14082026155437_IpcaNewspaperPublication.pdf)
- 2026-08-13 — Generic Announcement: IPCA Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_13082026133427_IpcaResultsQ1FY27.pdf)
- 2026-08-13 — Generic Announcement: IPCA Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_13082026173329_IpcaProceedingsofAGM.pdf)
- 2026-08-06 — Generic Announcement: Ipca Laboratories Limited will hold a conference call on August 14, 2026, at 15:30 IST to discuss its Q1 FY27 earnings and business update. The call follows the announcement of the company's Q1 FY27 financial results on August 13, 2026. Management representatives will include Mr. A K Jain and Mr. Harish Kamath, with Dam Capital Advisors Ltd. hosting the call. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_06082026133047_IpcaConcallIntimation14082026.pdf)
- 2026-07-28 — Official Filing: Ipca Laboratories Limited will hold a committee meeting on August 13, 2026, to consider unaudited standalone and consolidated financial results for the quarter ended June 2026. The trading window will be closed from July 1, 2026, to August 15, 2026.
- 2026-07-17 — Generic Announcement: Ipca Laboratories Limited will hold its 76th Annual General Meeting on August 13, 2026, via Video Conferencing. The company has issued letters to shareholders without registered email addresses, providing a web-link to access the Annual Report for the financial year 2025-26. This action complies with SEBI regulations requiring disclosure of the Annual Report's availability. Shareholders holding physical securities are reminded to update KYC details, including PAN and bank information, by a cut-off date of July 10, 2026, to ensure eligibility for payments. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_17072026152521_IpcaIntimationtononemailcases.pdf)
- 2026-07-15 — Generic Announcement: The filing announces the 76th Annual General Meeting (AGM) for Ipca Laboratories Limited, scheduled for August 13, 2026, to be held via Video Conferencing/Other Audio Visual Means. The record date for determining dividend entitlement is August 7, 2026. The company is providing e-voting facilities for its members, with remote e-voting commencing on August 10, 2026, and concluding on August 12, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_15072026123727_IpcaPostdespacthnotice.pdf)
- 2026-07-14 — Generic Announcement: Ipca Laboratories Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report, filed on July 14, 2026, details the company's performance and commitments across environmental, social, and governance (ESG) principles. It covers aspects such as energy and emissions, water management, waste management, employee well-being, human rights, and ethical business conduct. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_14072026110316_IpcaBRSR2026.pdf)
- 2026-07-14 — Generic Announcement: IPCA Laboratories has fixed Friday, August 7, 2026, as the Record Date for determining shareholder entitlement to a potential dividend of Rs. 6 per share (600%). This dividend, if sanctioned at the Annual General Meeting scheduled for August 13, 2026, will be paid on or before September 10, 2026, to shareholders of record on the specified Record Date. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_14072026160334_IpcaFormatforRecordDate.pdf)
- 2026-07-14 — Generic Announcement: Ipca Laboratories Ltd. will hold its 76th Annual General Meeting on August 13, 2026, at 3:30 p.m. via Video Conferencing. The company recommended a dividend of Rs. 6 per share for the financial year ended March 31, 2026, payable by September 10, 2026. August 7, 2026, is the record date for dividend entitlement, and remote e-voting will be open from August 10 to August 12, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_14072026155717_IpcaAGMNotice.pdf)
- 2026-07-13 — Generic Announcement: Ipca Laboratories Limited, on July 13, 2026, submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This certificate, received from their Registrar and Share Transfer Agent MUFG Intime India Pvt. Ltd., confirms compliance for the quarter ended June 30, 2026. MUFG Intime India confirmed that securities received for dematerialisation were processed and updated in the register of members within the prescribed timelines. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_13072026121236_Intimation_Reg_74_5_signed.pdf)
- 2026-07-07 — Credit Rating Update: On July 7, 2026, Ipca Laboratories Limited announced that India Ratings & Research affirmed its credit ratings. The rating for commercial paper, up to 365 days with a size of INR 500 million, was affirmed as IND A1+. The bank loan facilities rating was affirmed as IND AA+/Stable/IND A1+, with the facility size reduced from INR 25,937.30 million to INR 22,481.10 million. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_07072026121258_IpcaIndiaRatings2026.pdf)
- 2026-07-02 — Generic Announcement: Ipca Laboratories Limited will hold its 76th Annual General Meeting on August 13, 2026, via Video Conference/Other Audio Visual Means. The company will send the AGM notice and financial statements for FY 2025-26 via email to registered members. Additionally, a notice regarding the loss of a share certificate was published. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_02072026151356_IpcaNewspaperpreagmnotice.pdf)
- 2026-06-26 — Generic Announcement: Ipca Laboratories Ltd. approved the amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd. The appointed date for the scheme is April 1, 2026. For the financial year ended March 31, 2026, Ipca Laboratories reported total income of Rs. 7431 Crores, while Krebs Biochemicals reported Rs. 26 Crores. The amalgamation will involve a share exchange of 7 Ipca shares for every 200 Krebs shares, with no cash consideration. This merger aims to achieve operational synergies, cost optimization, and secure supply chains for APIs and drug intermediates. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_26062026131228_IpcaOutcomeofMeeting26062026.pdf)
- 2026-06-26 — Generic Announcement: Ipca Laboratories Ltd. approved the amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd. The appointed date for the scheme is April 1, 2026. For the financial year ended March 31, 2026, Ipca Laboratories reported total income of Rs. 7431 Crores, while Krebs Biochemicals reported Rs. 26 Crores. The amalgamation will involve a share exchange of 7 Ipca shares for every 200 Krebs shares, with no cash consideration. This merger aims to achieve operational synergies, cost optimization, and secure supply chains for APIs and drug intermediates. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_26062026131639_IpcaOutcomeofMeeting26062026.pdf)
- 2026-06-22 — Generic Announcement: Ipca Laboratories Limited will close its trading window for dealing in company securities from July 1, 2026, until 48 hours after the declaration of its unaudited financial results for the first quarter ended June 30, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The date of the board meeting to consider these results will be announced later. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_22062026105312_IpcaClosureofTradingWindow.pdf)
- 2026-06-12 — Press Release: On June 12, 2026, Ipca Laboratories Ltd. and Bhami’s Research Laboratory (BRL) announced a global licensing agreement. Ipca gains access to BRL's proprietary high-concentration subcutaneous biologics delivery platform for developing and commercializing monoclonal antibody products targeting oncology and inflammatory diseases worldwide. BRL will receive defined milestone fees and royalties on net sales upon commercialization. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_12062026173120_IpcaPressReleaseBhami12062026.pdf)
- 2026-06-09 — Generic Announcement: Ipca Laboratories Limited is issuing a newspaper notice to shareholders regarding the transfer of equity shares to the Investor Education and Protection Fund (IEPF) Authority. This action is in accordance with Section 124(6) of the Companies Act, 2013, and related rules, for shares where dividends have not been encashed for seven consecutive years or more. The company has uploaded details of affected shareholders on its website, and shares will be transferred to the IEPF Authority's demat account by September 17, 2026, if no communication is received from shareholders by that date. Shareholders can claim their shares and dividends from the IEPF. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_09062026124751_Newspaper_Intimation_signed.pdf)
- 2026-06-04 — Generic Announcement: Ipca Laboratories Limited held a Q4 FY26 earnings conference call on June 1, 2026, discussing financial performance and business updates. The company reported a 12% growth in domestic formulations to INR 853 crores for Q4 FY26 and a 10% growth for the full year to INR 3,817 crores. Export formulations grew 9% for the full year to INR 2,083 crores. Consolidated revenue for FY26 grew 8% to INR 9,646 crores. Stand-alone EBITDA margins improved to 25.18% for FY26, and consolidated EBITDA margins improved to 20.72%. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_04062026134811_IpcaConcallTranscript01062026.pdf)
- 2026-06-01 — Generic Announcement: Ipca Laboratories Limited announced a revised passcode link for a conference call scheduled for June 1, 2026, at 15:30 IST to discuss the company's Q4FY26 earnings and business update. — [Official attachment](https://nsearchives.nseindia.com/corporate/IPCALAB_01062026094231_IpcaConcallLinkRevised.pdf)

## News and market events

- 2026-09-18 — Mint: **Stock market today: Trade guide for Sensex, Nifty 50, crude oil and gold | Eight stocks to buy** — The Indian stock market is expected to open quietly on September 18, following mixed global cues. The Sensex ended slightly down, while the Nifty 50 was modestly up. Analysts suggest monitoring key resistance and support levels as geopolitical concerns persist. — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-trade-guide-for-sensex-nifty-50-crude-oil-and-gold-eight-stocks-to-buy-11789693227632.html)
- 2026-09-09 — Economic Times: **Why DSP Mutual Fund's Chirag Dagli is betting on CDMO, hospitals and smallcap healthcare stocks** — At the same time, the fund is evaluating hospital expansion, hybrid diagnostics businesses and valuations to identify healthcare companies capable of sustaining growth. — [Source](https://economictimes.indiatimes.com/markets/expert-view/why-dsp-mutual-funds-chirag-dagli-is-betting-on-cdmo-hospitals-and-smallcap-healthcare-stocks/articleshow/133951047.cms)
- 2026-09-08 — Economic Times: **Tata Capital Healthcare Fund to exit Linux Laboratories as ChrysCapital buys 20-25% stake** — Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Capital Healthcare Fund exit its entire holding. Linux Laboratories focuses on central nervous system therapies and has a strong brand portfolio. The company anticipates robust revenue and Ebitda growth in the coming years. This acquisition highlights continued private equity interest in India's pharmaceutical sector. — [Source](https://economictimes.indiatimes.com/news/company/corporate-trends/tata-capital-healthcare-fund-to-exit-linux-laboratories-as-chryscapital-buys-20-25-stake/articleshow/133939441.cms)
- 2026-09-02 — Mint: **Stock market today: Gift Nifty signals a negative start amid rising yields; 8 stocks to buy on Wednesday, 2 September** — As rising global bond yields and escalating US-Iran tensions loom, the Indian stock market braces for a negative open. Analysts suggest a cautious approach with stock-specific strategies, identifying potential buy opportunities amid the chaos.  — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-gift-nifty-signals-a-negative-start-amid-rising-yields-8-stocks-to-buy-on-wednesday-2-september-11788312282518.html)
- 2026-08-18 — Mint: **Raja Venkatraman recommends three stocks for 18 August | Stock Market News** — Market expert Raja Venkatraman shares his top stock picks for 18 August. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-three-stocks-18-august-11786982882569.html)
- 2026-08-17 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty falls to 24,250; Infosys, HCLtech top losers** — Stock Market Live Updates: We are in the second half of the day's trade, and the markets are looking to mark a recovery from the day's low. The markets are under pressure, as indices trade lower at the beginning of a new week. The Nifty is down nearly 80 points, falling below the 24,300 mark. Infosys, Tata Motors PV and HCLtech are top losers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-reliance-hdfc-bank-cochin-nmdc-voltas-gmr-jupiter-share-price-liveblog-19970547.htm)
- 2026-08-17 — MONEYCONTROL: **Buy Ipca Laboratories; target of Rs 1950: Emkay Global Financial** — Emkay Global Financial, Ipca Laboratories, buy, Recommendations — [Source](https://www.moneycontrol.com/news/business/stocks/buy-ipca-laboratories-target-of-rs-1950-emkay-global-financial-14007250.html)
- 2026-08-17 — BUSINESSTODAY: **Ipca Laboratories shares jump 12% to hit record high on strong Q1 show; check revised target prices** — Ipca Laboratories, Ipca Laboratories shares, Ipca Laboratories Q1 FY27 results, Ipca Laboratories share price, Ipca Laboratories target price, Ipca Laboratories stock, pharma stocks, pharmaceutical stocks, JM Financial, Nuvama Institutional Equities, Motilal Oswal Financial Services, Ipca Laboratories Buy rating, Ipca Laboratories revised target price, Ipca Q1 results, Ipca Laboratories earnings, Unichem Laboratories, pharma sector, stock ma — [Source](https://www.businesstoday.in/markets/stocks/story/ipca-laboratories-shares-jump-12-to-hit-record-high-on-strong-q1-show-check-revised-target-prices-549498-2026-08-17)
- 2026-08-13 — The Hindu: **Q1 Results Today Live: TMPV Q1 PAT falls, Max Health PAT flat, Solar Ind, IPCA Lab, TVS Srichakra, V2 Retail, Honasa Consumer, Minda Corp PAT up, LG Electronics, Amber Enterprises, Brigade, JSW Cement to announce Q1 results** — Q1 Results Today, 13th August 2026 Live Updates: Follow Q1FY27 live updates from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-solar-ind-tmpv-lg-electronics-max-healthcare-gic-godrej-ind-jubilant-foodworks-amber-enterprises-brigade-jsw-cement-honasa-consumer-tmcv-hal-results-13-august-2026/article71335955.ece)
- 2026-08-13 — The Hindu: **Sensex today | Stock Market Live: Sensex down nearly 200 points at 77,770, Nifty slides 92 points in late trade** — Sensex, Nifty, Share Prices Live: At 3 pm, Sensex traded 195.93 pts or 0.25% lower at 77,770.42, and NIfty 50 declined 92.70 pts or 0.38% to 24,343.25.  Indian equities remained subdued despite stronger Asian markets, with firm crude prices and geopolitical risks keeping investors cautious. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-13th-august-2026/article71337670.ece)
- 2026-08-13 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty below 24,400; TVS Srichakra jumps 8% after results** — Sensex Today | Stock Market LIVE Updates: We are in the second half of this Sensex weekly expiry session, and the markets are under pressure again, as the Nifty index falls close to 50 points, falling below 24,350. The Nifty bank index is taking a heavier blow, down over 300 points. Grasim, Ultratech and Hindalco are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-expiry-today-nifty-50-msci-gcpl-lg-tata-motors-lenskart-laurus-adani-ashok-leyland-share-price-liveblog-19968111.htm)
- 2026-08-06 — Mint: **Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 6 August 2026** — Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today — BLS International Services, Usha Martin, 360 One Wam, Netweb Technologies India, and IPCA Laboratories. — [Source](https://www.livemint.com/market/stock-market-news/breakout-stocks-to-buy-or-sell-sumeet-bagadia-recommends-five-shares-to-buy-today-6-august-2026-11785976757322.html)
- 2026-07-18 — Times of India: **Meet Premchand Godha: The CA who managed Amitabh Bachchan's finances and built a struggling pharma company into a Rs 28,000 crore giant** — Trending News: Premchand Godha's success story is one of India's most remarkable business journeys. Long before he became a billionaire businessman, Godha worked as . — [Source](https://timesofindia.indiatimes.com/etimes/trending/meet-premchand-godha-the-ca-who-managed-amitabh-bachchans-finances-and-built-a-struggling-pharma-company-into-a-rs-28000-crore-giant/articleshow/132482610.cms)
- 2026-07-15 — The Hindu: **Sensex today | Stock Market Live: Stock to buy today: Caplin Point Laboratories** — Sensex, Nifty, Share Prices LIVE: The short-term outlook is bullish for Caplin Point Laboratories. The stock has been consolidating within its broader uptrend for more than two weeks between ₹2,500 and ₹2,700. We expect the stock to make a bullish breakout above ₹2,700 and resume the broader uptrend. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-15-july-2026/article71220956.ece)

## Business profile

**Strategic vision:** Manufactures and supplies active pharmaceutical ingredients and formulations.

### Business segments
- **Pharmaceutical Manufacturing:** The company develops and produces a wide range of formulations and APIs, catering to various therapeutic areas such as pain management, rheumatology, antimalarials, and hair care.

### Competitive strengths
- Integrated manufacturing of APIs and formulations
- Broad portfolio of products across multiple therapeutic areas
- Extensive international distribution network

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.25%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.78%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.80%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +2.21%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — +0.12%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/ipcalab
Markdown representation: https://faxioms.com/stocks/ipcalab?render=md